Press releaseACCESS Newswire
Regentis Biomaterials
RGNT · NYSE
$1.28−$0.12 (−8.57%)TodayMarket closed ·
Prev close $1.40
Latest news
- Press releaseACCESS Newswire
Regentis Biomaterials to Present at the 2026 ThinkEquity Conference on October 15 in New York City
- Press releaseGlobe Newswire
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Ehud Geller, CEO of Regentis Biomaterials Ltd.
- Press releaseACCESS Newswire
Regentis Biomaterials Reports First Half 2026 Financial Results and Provides Corporate Update
- Press releaseACCESS Newswire
Regentis Receives Japanese Patent allowance, Strengthening its Global GelrinC Intellectual Property Portfolio with New Proprietary Manufacturing Technology
- News
Regentis Biomaterials Receives European Regulatory Approval For New GelrinC Manufacturing Process
- Press releaseACCESS Newswire
Regentis Receives European Regulatory Approval for New GelrinC Manufacturing Process, Increasing Production Yield by 400% Ahead of European Commercial Launch
- Press releaseACCESS Newswire
Regentis Biomaterials Announces Pricing of a $6.5 Million Private Placement
- NewsKaustubh Bagalkote
Why Is Regentis Biomaterials Stock Rising On Wednesday?
- News
12 Health Care Stocks Moving In Monday's After-Market Session
- NewsAvi Kapoor
Crude Oil Tumbles Over 5%; Empire State Manufacturing Index Falls In June
- News
Regentis Biomaterials Shares Halted, News Pending
- NewsAvi Kapoor
Dow Jumps Over 600 Points Following US-Iran Peace Deal
- Press releaseACCESS Newswire
Regentis to Commence European Surgeon Training for GelrinC in Knee Cartilage Repair as Commercial Launch Preparations Accelerate
- News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- NewsAvi Kapoor
Why Sterling Infrastructure Shares Are Trading Higher By Over 22%; Here Are 20 Stocks Moving Premarket
- Press releaseACCESS Newswire
Regentis Implements Strategy for Commercial Deployment of GelrinC(R) in Europe Through Collaboration with Humanitas Hospital and Leading Cartilage Repair Expert Prof. Elizaveta Kon
- Press releaseACCESS Newswire
Regentis Biomaterials Develops and Patents New Solvent-Free Manufacturing Process That Increases GelrinC Production Yield by 400%
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.